Timestamps

Speaker 1: (01:17)
 Can you tell us why that decision was made and how you went about bringing up this new test? 

Speaker 1: (04:27)
 We went with our laboratory developed test, which was essential to get us up and running, but had a limited throughput. Then you've basically tripled our capacity by adding these additional platforms and tests.

Speaker 1: (05:27)
 Now I also know when you verified this, you really turned it around amazingly fast. Can you tell us a bit about that? 

Speaker 1: (06:46)
 That is amazing. Now you mentioned the assay has received EUA—emergency use authorization—from the Food and Drug Administration or FDA. Now what specimens does this assay have EUA for? 

Speaker 1: (07:31)
 Are you adding additional specimen types to what you're accepting for this assay? 

Speaker 1: (09:23)
 How are you using this assay today and what is your total capacity for testing? 

Speaker 1: (11:41)
 Now you've also brought in another test. How was that decision made and do you want to tell us a little bit about that? 

Speaker 1: (14:34)
 Now, I don't believe before this that you were working 24/7, is that correct? 

Resources:

https://news.mayocliniclabs.com/covid19/